Zhao, Cheng, et al. Science Bulletin 64.19 (2019): 1418-1425.
Sucralfate, a mucosal adhesive agent, has been employed in the development of biomimetic intestinal barriers to prevent intestine-derived diseases, including obesity. In this study, sucralfate was encapsulated in microfluidic-generated microcapsules, which were designed to mimic the natural intestinal barrier. The microcapsules were composed of stomach-tolerant dietary-fiber shells and controllable sucralfate cores, engineered through microfluidic electrospray to achieve precise control over the size, morphology, and release profiles of the capsules.
The encapsulated sucralfate core provides an effective bioadhesive that forms a continuous mechanical barrier on the intestinal wall, protecting the mucosa and blocking harmful luminal contents. In vitro and in vivo studies demonstrated that these biomimetic barriers effectively reduced food fermentation in the gut, prevented fat generation, and lowered disease risk factors, including the prevention of high-fat-diet-induced obesity.
The precise control of microcapsule characteristics enabled the protection of sucralfate from gastric acid, and its gradual release allowed for continuous intestinal protection. This study illustrates the potential of sucralfate-based biomimetic barriers as a promising strategy for treating and preventing intestinal diseases by maintaining intestinal function and modulating gut health. Such innovations could lead to novel therapeutic approaches for obesity and other related gastrointestinal disorders.
Le, Zhicheng, et al. Biomaterials 311 (2024): 122700.
Sucralfate, known for its adhesive properties, has been innovatively utilized in bioactive microneedles (SUC-MN) to enhance wound healing. This technology employs a two-stage strategy that synergistically delivers interleukin-4 (IL-4) to accelerate the healing process. In the first stage, SUC-MN reprograms macrophages towards a pro-regenerative M2 phenotype via the JAK-STAT pathway, thereby boosting endogenous growth factor (GF) production. In the second stage, sucralfate's binding affinity to GFs protects them from protease degradation, significantly improving their bioavailability at the wound site.
This dual mechanism was shown to accelerate wound healing by 56.6% in diabetic mice and 46.5% in porcine models compared to untreated controls. The bioactive microneedle system not only promotes cell proliferation and angiogenesis but also provides sustained GF delivery, making it an ideal candidate for treating challenging wound types such as diabetic and burn wounds. Additionally, as all components of this technology are derived from FDA-approved or GRAS materials, it holds strong potential for clinical application.
In conclusion, sucralfate-based microneedles represent a novel, minimally invasive approach to wound healing, leveraging both immune modulation and GF protection to optimize therapeutic outcomes. Further studies, particularly involving humanized models, are necessary to validate the full clinical potential of this innovative technology.
CONNECT WITH US
Interested in our Services & Products ?
Need detailed information?
Terms & Conditions
Privacy Policy | Cookie Policy | Copyright © 2025 Alfa Chemistry. All rights reserved.
PAGE TOP
